Pliant Therapeutics (PLRX) PT Lowered to $49 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PLRX Hot Sheet
Price: $0.86 --0%
Rating Summary:
4 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
4 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Jeff Jones lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $49.00 (from $52.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $465 at Cantor Fitzgerald
- Sprout Social Inc. (SPT) PT Raised to $13 at Cantor Fitzgerald
- Pfizer Ltd (PFIZ:IN) PT Lowered to INR4,800 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
